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Introduction
Narcolepsy type 1 (NT1) is a rare disorder of the regulation of sleep and wakefulness with an incidence of 1 per 100,000 person years and a prevalence ranging between 20-50 per 100,000
individuals (Ohayon et al., 2002 , Wijnans et al., 2013 . The disorder is characterised by five core symptoms: excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis and disturbed nocturnal sleep. These symptoms arise as a result of the destruction of over 90 percent of hypocretin (Hcrt)-producing neurons in the lateral hypothalamus (Peyron et al., 2000 , Thannickal et al., 2000 . Unfortunately, causal treatment of the disorder is not yet available.
In pursuit of the disease mechanism, two findings have shifted the focus of narcolepsy research to the hypothesis that the destruction of Hcrt-producing neurons is caused by an auto-immune process. First, 95% of NT1 patients carry the HLA-DQA1*01:02 / DQB1*06:02 haplotype encoding HLA-DQ6, an HLA-class II molecule expressed on antigen-presenting cells (Juji et al., 1984 , Mignot et al., 1997 , Tafti et al., 2014 , which was later complemented by genome-wide association studies that showed variants within immune system-regulating genes in narcolepsy patients A C C E P T E D M A N U S C R I P T Han et al., 2013 , Hor et al., 2010 . Second, an increase in the incidence of NT1 has been observed in several European countries after the 2009 H1N1 influenza pandemic, and the subsequent vaccination campaign , Feltelius et al., 2015 , Lind et al., 2014 , Partinen et al., 2012 . Even though there was no wide-spread vaccination campaign in Asian countries, an increased incidence has also been reported in China (Han et al., 2011) . This suggests that NT1 might develop as the result of a cross-reactive anti-viral immune response that leads to the destruction of Hcrtproducing neurons. More insight in this reaction could pave the way for causal treatment development in NT1 and potentially also prevention of the disease by identifying individuals at-risk.
Research on the auto-immune reaction has focused on two candidate immune cell types that could drive this reaction leading to NT1: cross-reactive B cells and cross-or autoreactive CD4+ T cells. Four studies (Black et al., 2005 , Overeem et al., 2006 , Tanaka et al., 2006 , van der Heide et al., 2015 failed Hcrt-specific T cell responses have recently been described (Latorre et al., 2018) , this does not explain the strong link with HLA-DQ6. In short, the molecular mechanism underlying the HLA-DQ6 association remains to be determined.
Based on the increased incidence of NT1 after the H1N1 influenza pandemic mentioned above, we aimed to assess whether H1N1 influenza reactive CD4+ T cells are present in NT1 patients. A secondary aim was to assess whether these H1N1 influenza specific CD4+ T cells cross-react with Hcrt. We determined the crystal structure of one earlier identified H1N1 hemagglutinin peptide and two Hcrt peptides bound to the disease-predisposing HLA-DQ6 molecules to assess structural homology. Subsequently, we stimulated peripheral blood mononuclear cells with these peptides to generate specific T cell lines and clones. We then performed proliferation tests on these clones to assess both H1N1-and Hcrt-reactivity and assess HLA-DQ6 restriction, cross-reactivity and T cell receptor sequence of these clones.
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Materials and methods
Subjects
Between . This assay has an intra-assay variability of <5% and a A C C E P T E D M A N U S C R I P T detection limit of 50 pg/mL. To adjust for inter-assay variability, Stanford reference CSF samples were included in the assay (Ripley et al., 2001 , Mignot et al., 2002 .
Peptides
All peptides used were produced at the Peptide Synthesis Facility of the Department of produced essentially as described previously for HLA-DQ2 (Henderson et al., 2007 , Petersen et al., 2014 . Briefly, the αβ-heterodimer of the HLA-DQ6 extracellular domain was expressed in Hi5 insect cells, with each peptide linked to the N-terminus of the HLA-DQ6 β-chain. The C-termini of the constructs contained an enterokinase cleavable Fos/Jun zippers, and, at the C terminus of the β-chain, a BirA biotinylation sequence followed by a His10-Tag. The complexes were purified via diafiltration, metal affinity, size exclusion and ion exchange chromatography. For crystallisation experiments the Fos/Jun zippers were removed by enterokinase cleavage and ion exchange chromatography.
Crystallisation, data collection, structure determination and refinement
Peptide-HLA-DQ6 complexes were crystallised at 20C via the hanging drop vapor diffusion method using equal volumes of mother liquor and protein solution at 10 mg/ml in a buffer containing 10mM
Tris (pH 8) and 150 mM NaCl. HLA-DQ6-Hcrt 56-68 and HLA-DQ6-Hcrt 87-99 were crystallised with mother liquor containing 16-20% PEG4000, 0.1M NaOAc pH4.5-5.0, and HLA-DQ6-HA 275-287 was crystallised with 23% PEG4000, 0.2M NaI, 0.1M HEPES pH 7. Prior to data collection the crystals were cryoprotected in mother liquor supplemented with 20% glycerol, or 20% ethylene glycol in the case of HLA-DQ6-Hcrt 87-99 , and flash frozen in liquid N 2 . X-ray diffraction data was collected at the mx2 beamline of the Australian Synchrotron using a ADSC Q315r detector and data processing was
carried out with XDS (Kabsch, 2010) and Scala (Evans, 2006) . The crystal structures were solved by molecular replacement in Phaser (McCoy et al., 2007 ) using a published HLA-DQ6 structure (PDB code 1UVQ) as search model. The structural models were refined by iterative rounds of model building in Coot (Emsley et al., 2010 ) and restrained refinement in Phenix (Adams et al., 2010) . For further details on data collection and refinement statistics, see Table 1 .
Peripheral blood mononuclear cell (PBMC) isolation
Blood was drawn from all patients and healthy controls. PBMCs were extracted using Ficoll-Paque (GE Healthcare, Chicago, USA) gradient reagent. The first experiments were performed on fresh
PBMCs, but in the remainder the isolated PBMCs were subsequently frozen in 10% dimethyl sulfoxide (DMSO; Sigma Aldrich, Saint Louis, USA) in fetal calf serum (FCS; Sigma Aldrich, Saint Louis, USA). These samples were stored until use in liquid nitrogen vessels.
Antigen-specific T cell lines
After isolating or thawing of PBMCs of narcolepsy type 1 patients and healthy controls, 
Peptide-specific T cell clone generation
Peptide-specific T cell clones (TCCs) were generated from T cell lines specific for H1N1-HA 275-287 from 3 narcolepsy patients by limiting dilution in culture medium containing 10 6 irradiated feeder cells/mL, 20 U/mL rIL-2, 10 ng/mL IL-15 and 1 µg/mL PHA ("feeder mix"; Remel, Lenexa, USA). The cells were stimulated with 20 U/mL rIL-2 and 10 ng/mL in 10% human serum/IMDM after 5 days.
After 10 days, growing wells were transferred to 24-well plates and cultured in feeder mix until a confluent layer of cells was formed. For the T cell lines of 9 narcolepsy patients, streptavidin-PE-HLA-DQ6-H1N1-HA 275-287 and streptavidin-PE-HLA-DQ6-Hcrt 56-68 and -Hcrt 87-99 tetramers were used to directly stain HLA-H1N1-HA 275-287 -, -Hcrt 56-68 -and -Hcrt 87-99 -specific T cells. Tetramers were produced essentially as described (Ooi et al., 2017) . These tetramer-positive CD4+ T cells were sorted by flow cytometry on a FACS-Aria III instrument (BD Biosciences) and expanded as described above. Clones were subsequently generated from the identified H1N1-HA 275-287 -specific and/or Hcrt 56-68 -or Hcrt 87-
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99 -specific T cells, as described previously (Kooy-Winkelaar and Koning, 2015) . All T cell lines used for TCC generation were derived from frozen narcolepsy patient samples.
Flow cytometry
Peptide-specific T cell lines generated from one patient were incubated for 30 minutes with 11
antibodies for surface staining and subsequently acquired on a LSRII instrument (BD Biosciences).
Fluorochrome-labelled antibodies directed against CD3 (clone UCHT1), CD4 (clone SK3), CD5 (clone
CD45RA (clone L48) and IgG1 (clone MOPC-21) were from BD Biosciences (San Jose, California, USA),
anti-CD8 (clone 3B5) was from Invitrogen (Bleiswijk, the Netherlands) and anti-CD45 (clone HI30) from eBioscience (San Diego, California, USA). Results were analysed using FlowJo V.10 software (Schmitz et al., 2016) .
T cell proliferation assay and assays for assessing HLA-DQ6 restriction
Proliferation assays were performed on T cell lines and locally produced) were added to the initial assay.
T cell receptor (TCR) sequencing
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TRAV, TRBV and CDR3 gene segment sequences of H1N1-HA 275-287 -specific TCCs were amplified using PCR and a set of specifically designed primers. PCR products rendered in this way were cloned into a Promega pGEM-T Easy vector and subsequently sequenced. The TRAV and TRBV gene usage and CDR3 sequences for all generated clones were determined using IMGT/V-QUEST (Brochet et al., 2008) .
Statistical analysis
Differences at baseline in participant characteristics were calculated with Student's t-tests and
Pearson's chi-square test. Pearson's chi-square test was also used for comparing T cell proliferation in narcolepsy patients as compared to healthy controls. Differences between conditions in the HLA blocking experiments were calculated by one-way ANOVA with a Bonferroni post hoc analysis.
Differences between P-values below 0.05 were deemed significant. Bonferroni corrections were executed when needed. All analyses were conducted using the IBM SPSS Statistics 23 software package.
Results
Patient characteristics
We included 81 narcolepsy type 1 patients and 19 healthy controls. Patient characteristics are shown in Table 2 . Notably, all narcolepsy type 1 patients except one were HLA-DQA1*01:02/DQB1*06:02 (HLA-DQ6) positive. Thirty-four patients had undergone a lumbar puncture for Hcrt-1 measurement;
all had Hcrt-1 values in the cerebrospinal fluid that were below the cut-off value of 110 pg/mL based on the ICSD-3 criteria for narcolepsy type 1. Narcolepsy type 1 patients were younger than healthy controls, but the distribution of males and females was comparable between the two groups. conformations. Within the 9-mer core of the bound peptides, the most notable differences were observed in the exposed positions p2 and p8 of the peptides (p2-histidine and p8-threonine in the Hcrt complexes, and p2-alanine and p8-isoleucine in the H1N1-HA complex). In addition to the differences in peptide sidechains, we observed a difference in the β-chain helix, which was positioned closer to the peptide in the H1N1-HA complex when compared to the two Hcrt complexes. This homology prompted us to determine whether this could also lead to T cell crossreactivity to the H1N1-HA and hypocretin peptides in functional experiments.
HLA-DQ6-H1N1-HA 275-287 -specific CD4+ T cells are readily detectable in narcolepsy type 1 patients and healthy controls, but do not cross-react with HLA-DQ6-Hcrt 56-68 or -Hcrt 87-99
T cell lines were generated from PBMCs of narcolepsy type 1 patients and healthy controls by co- Analyses revealed a dominance of CD4+ T cells in these T cell lines (Figure 3 ).
T cell reactivity to H1N1-HA 275-287 is HLA-DQ6-restricted
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T cell clones (TCCs) were generated from the H1N1-HA 275-287 -reactive T cell lines of 12 narcolepsy type 1 patients by either limiting dilution (in T cell lines of 3 narcolepsy type 1 patients) or isolation using streptavidin-PE-HLA-DQ6-H1N1-HA 275-287 tetramers (in T cell lines of 9 narcolepsy type 1 patients) and tested for reactivity against H1N1-HA 275-287 . In TCCs generated from all H1N1-HA 275-287 -specific CD4+ T cell lines, H1N1-HA 275-287 -specific clonal T cell responses were found (Table 3) .
To assess HLA-DQ6 restriction, T cell proliferation experiments were performed with irradiated peptide. Furthermore, when T cell proliferation experiments were performed with irradiated allogeneic PBMCs expressing HLA-DQ6, an anti-HLA-DQ mAb was able to block T cell proliferation of the generated TCCs. An anti-HLA-class I mAb blocked T cell proliferation considerably less effectively, whereas anti-HLA-DR and -DP mAbs did not affect T cell proliferation ( Figure 4A-B) . These experiments confirm that the detected H1N1-HA 275-287 -specific CD4+ T cell proliferation is HLA-DQ6-restricted.
The HLA-DQ6-H1N1-HA 275-287 -specific T cell receptor repertoire in narcolepsy type 1 patients and healthy controls shows no biased expression
Recent reports describe a bias in TCR sequences for recognition of peptide-HLA complexes in CD4+ T cell mediated diseases (Qiao et al., 2014 , Petersen et al., 2014 ). Since we were not able to show significant differences between percentages of narcolepsy type 1 patients and controls with HLA-DQ6-H1N1-HA 275-287 -specific T cells, we searched for differences in the T cell repertoire used by narcolepsy type 1 patients and controls to mount immune responses to this antigen. TCRs expressed by 20 H1N1-HA 275-287 -specific TCCs from 4 narcolepsy type 1 patients and 4 H1N1-HA 275-287 -specific
TCCs from 2 healthy controls were sequenced (Table 4) . 18 TCR sequences were identified in TCCs of narcolepsy type 1 patients; 4 different TCR sequences in TCCs of healthy controls. There was expansion of some clones within a given patient, but these likely arose during the culturing process, with some T cell clones responding better to peptide hence expanding at a greater rate than others subsequently skewing the representative pool. Nevertheless, although only a small sample size was interrogated, no evidence for a biased TRAV, TRBV or CDR3 sequence motif was observed across unrelated individuals with narcolepsy type 1 or in healthy controls.
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Discussion
HLA-DQ6-H1N1-HA peptide-specific CD4+ T cell responses were readily detected in both narcolepsy type 1 patients and healthy controls, with a higher proportion in the narcolepsy type 1 group. We did not detect HLA-DQ6-Hcrt peptide-specific T cell responses. Our experiments do not support the hypothesis that these Hcrt peptides are implicated in cross-reactivity leading to Hcrt-producing neuronal destruction and, thereby, to narcolepsy type 1.
The HLA-DQ6-H1N1-HA peptide-specific TCCs did show some, but no extensive clustering of T cell receptor sequences in narcolepsy type 1 patients. Larger studies would be required to determine if the H1N1-specific TCR repertoire in NT1 patients differs from controls.
Our findings add to those of others in the field who did show antibody-mediated reactivity to H1N1-HA in narcolepsy type 1 patients. Several groups found H1N1-HA specific antibodies in narcolepsy type 1 patients (Lind et al., 2017 , Lind et al., 2014 , but H1N1-HA specific T cells have not been described. The lack of reactivity to Hcrt peptides was reported in studies focusing on autoantibodies (Black et al., 2005) and CD4+ T cells (Ramberger et al., 2017 , Kornum et al., 2017 . HLA-DR-restricted
Hcrt-specific T cell responses have recently been described (Latorre et al., 2018) , but that study does
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not explain the strong link with HLA-DQ6. Interestingly, one other study (Ramberger et al., 2017) reported reactivity to Hcrt-peptide pools in a small minority of narcolepsy type 1 patients, although the peptides used differed from the ones in the current study.
Moreover, in our current study we focused on H1N1-HA and Hcrt peptides that display sequence homology, which does not rule out that other H1N1 peptides are involved. Another possibility is that the key differences between the peptides, a histidine residue at position 59 and 90 of the Hcrt [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] and Hcrt 87-99 peptides, respectively, as compared with an alanine residue in the corresponding position in the H1N1-HA 275-287 peptide, may prevent cross-reactive responses. We therefore also tested substitution variants of the Hcrt-peptides in which the histidine residues were replaced by an alanine, but we observed no cross-reactivity to these peptides as well, making it unlikely that posttranslational modification of Hcrt-peptides underlies cross-reactivity (results not shown). In future studies we will therefore be testing T cell responses to peptide pools representing the H1N1 proteome and preprohypocretin.
One of the limitations in our study is that we have not been able to distinguish between narcolepsy type 1 patients and healthy controls that have actually encountered the H1N1 influenza virus and those who have not. We could therefore not be sure whether different exposure to the virus explains the lack of differences in H1N1-HA peptide-specific T cell responses between narcolepsy patients and healthy controls. However, T cell mediated cross-protective immunity generated by previous H1N1 infections was found to be common in the population (Miller et al., 2010) .
Another limitation in our study is that we are performing our experiments in blood, while the actual destruction of Hcrt-producing neurons is taking place at the other side of the blood-brain barrier. It was recently described that T cell composition in cerebrospinal fluid differed between narcolepsy type 1 patients and healthy controls (Moresco et al., 2018) . Repeating our experiments in cerebrospinal fluid would therefore be a better environment to test for cross-reactive T cells.
Additionally, detecting proliferation of a small immune subset that could have driven the destruction of the approximately 80,000 Hcrt-producing neurons (Thannickal et al., 2000) in a vast number of non-proliferating immune cells is technically difficult. The procedure used for peptide-specific TCC generation was also used in previous studies for the isolation of HLA-DQ-restricted gluten-specific T cell clones from patients with celiac disease in which we have determined the affinity of such T cells for the cognate HLA-DQ-gluten complexes. We observed that in cell-free assays the affinity values for some of these HLA-DQ-gluten specific TCRs were comparable with affinity values observed for microbial or non-self TCR-pMHC-II interactions, while others exhibited affinity values in line with those of low-affinity autoreactive TCR-pMHC complexes (Petersen et al., 2014) . In cellular assays similar substantial differences were observed (Broughton et al., 2012) . Therefore, this indicates that A C C E P T E D M A N U S C R I P T our method allows the identification of both high-and low-affinity T cell clones. However, we cannot exclude the possibility that with our technique we missed the detection of very low frequency T cells. The T cell library method that was performed in a recent publication on T cell reactivity to Hcrt (Latorre et al., 2018) would be an interesting technique to screen for these low frequency clones.
Other novel approaches, such as mass cytometry, to address this rare immune subset problem are emerging with techniques that can isolate disease-specific immune subsets with unprecedented detail (van Unen et al., 2017) . Repeating our experiments with only those subsets that are specific for narcolepsy type 1, would significantly increase the odds of identifying rare cross-reactive immune cells in narcolepsy type 1 patients should they exist.
Conclusions
We identified HLA-DQ6-restricted H1N1-HA peptide-specific T cell responses in a subset of narcolepsy type 1 patients and healthy controls. We did not find HLA-DQ6-H1N1-HA peptide-specific T cells cross-reactive to Hcrt-2 peptides. These results indicate that it is unlikely that cross-reactivity between H1N1-HA and Hcrt-2 peptides presented by HLA-DQ6 is involved in the development of narcolepsy. A = alanine; C = cysteine; CDR3 = complementarity-determining region 3; D = aspartic acid; E = glutamic acid; F = phenylalanine; G = glycine; H = histidine; I = isoleucine; K = lysine; L = leucine; M = methionine; N = asparagine; P = proline; Q = glutamine; R = arginine; S = serine; T = threonine; TRAJ = T-cell receptor alpha joining segment; TRAV = T-cell receptor alpha variable segment; TRBD = T-cell receptor beta diversity segment; TRBJ = T-cell receptor beta joining segment; TRBV = T-cell receptor beta variable segment; V = valine; W = tryptophan; Y = tyrosine. 
Highlights:
 Hypocretin and H1N1-hemagglutinin peptides bound to HLA-DQ6 show structural homology  H1N1-hemagglutinin-specific CD4+ T cells detected in narcolepsy type 1 patients and controls  Cross-reactivity between H1N1-hemagglutinin and hypocretin peptides not observed  H1N1-hemagglutinin-specific CD4+ T cell reactivity is HLA-DQ6-restricted
